The recent volatility surrounding Radius Health shares should lessen as the market starts focusing on its osteoporosis drug Abaloparatide, said the company's CEO Robert Ward. Radius Health sold 6.5 million shares of stock $8 a share in a June IPO, raising $52 million. Abaloparatide is in Phase III development and has exhibited faster improvement in bone mineral density at all sites in a pair of confirmatory Phase II studies. Ward said he expects the pivotal trial readout in December and hopes to submit and NDA in mid-2015. Ward said the company has not partnered with a larger drug company yet, and has raised more than enough money to get Abaloparatide to market.

More from Video

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Stocks Trade Mixed in Further Trump Trade News and 4 Other Stories You Must Know

Stocks Trade Mixed in Further Trump Trade News and 4 Other Stories You Must Know

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

One-on-One With Carnival Corporation CEO Arnold Donald (Watch)

One-on-One With Carnival Corporation CEO Arnold Donald (Watch)